The Latest Cardiac and Vascular News
Enabling a time-efficient workflow and better-informed clinical decision making for structural heart interventions GENT, Belgium–(BUSINESS WIRE)–FEops announced today its new release of FEops HEARTguide™, including an AI-based anatomical analysis of MSCT images for the pre-operative planning of structural heart interventions. With this introduction, physicians don’t need to do the measurements […]
SHANGHAI, June 29, 2023 /PRNewswire/ — Bioheart (02185.HK), together with its holding subsidiary Angiocare announces the clinical result for Iberis-HTN at China Interventional Therapeutics 2023. Iberis-HTN is a prospective, multicenter, blinded, randomized controlled trial to evaluate the safety and efficacy of the Iberis® Multi-Electrode Renal Artery Radiofrequency Ablation Catheter System for the treatment […]
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has set a date of September 13, 2023 for the meeting of the Cardiovascular and Renal Drugs Advisory Committee to review the supplemental New Drug Application for patisiran, an […]
CAMBRIDGE, England, June 29, 2023 /PRNewswire/ — PocDoc, the Cambridge-based digital health platform, today announces a major pilot with the NHS Targeted Lung Health Check programme in the North East, in partnership with cardiologist Dr Alan Bagnall and the NIHR Clinical Research Network North East and North Cumbria (CRN NENC). As documented widely in recent weeks, the NHS England Targeted […]
SEOUL, Korea, June 28, 2023 (GLOBE NEWSWIRE) — Kalos Medical Inc. (“Kalos Medical”), a developer of innovative medical devices treating hypertension and other chronic illnesses, announced on June 23rd that South Korea’s Ministry of Food and Drug Safety (“MFDS”) designated the company’s DENEX hypertension treatment system as an Innovative Medical […]
Global clinical study aims to broaden evidence base by assessing clinical and economic benefits for the FFRangio System First patient enrolled at Ascension St. John Hospital in Michigan KFAR-SABA, Israel and IRVINE, Calif., June 28, 2023 /PRNewswire/ — CathWorks announced today that the first patient has been enrolled in the Advancing Cath Lab Results with FFRangio Coronary Physiology […]
– Seeking inclusion of CV risk reduction indications in Europe – – Anticipated approvals in Europe in the first half of 2024 – ANN ARBOR, Mich., June 28, 2023 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced that the application was filed for a Type II(a) variation with the European Medicines Agency (EMA) […]
Liquidia exclusively licenses North American rights to L606, an inhaled formulation of treprostinil administered twice-daily with a short duration, next-generation nebulizer Liquidia funds $10 million upfront payment from finance agreement with HealthCare Royalty Pharmosa to receive up to $215 million in development and sales milestones for PAH and PH-ILD indications, […]
CAMZYOS is the first and only cardiac myosin inhibitor approved in the European Union Approval based on two positive Phase 3 trials, EXPLORER-HCM and VALOR-HCM, demonstrating significant benefit in patients treated with CAMZYOS versus placebo PRINCETON, N.J.–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved CAMZYOS® (mavacamten, 2.5 mg, 5 […]
ATCOR and Datacubed Health partner on a novel remote trial solution to integratedigital vascular biomarker patient monitoring within the Datacubed Health PatientEngagement Platform IRVINE, Calif., June 26, 2023 /PRNewswire/ — ATCOR Medical, subsidiary of CardieX and developer of innovative medical devices and digital solutions to personalize healthcare and improve clinical trial patient outcomes, today announces it […]
